AQST

Aquestive Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth 2/10
  • Value 0/10
Aquestive Therapeutics sales and earnings growth
AQST Growth
Fair
  • Revenue Y/Y -22.61%
  • EPS Y/Y -52.94%
  • FCF Y/Y -47.54%
Aquestive Therapeutics gross and profit margin trends
AQST Profitability
Low
  • Gross margin 58.30%
  • EPS margin -188.10%
  • ROIC 5Y -20.80%
Aquestive Therapeutics net debt vs free cash flow
AQST Risk
Poor
  • Debt / Equity 999.0
  • Debt / FCF 0.2
  • Interest coverage -3.9

Aquestive Therapeutics stock volatility is in-line with the overall market. We give it a Poor risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗